Skip to main content

Methods to Evaluate Novel Hepatitis C Virus Vaccines

  • Protocol
  • First Online:
Vaccine Design

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1403))

Abstract

The hepatitis C virus (HCV) is a major cause of severe liver disease worldwide. It is estimated that around 130–170 million individuals are chronic carriers of the infection and they are over time at an increased risk of developing severe liver disease. HCV is often referred to as a silent epidemic because the majority of infected individuals do not develop any symptoms. Hence, many individuals are diagnosed at a late stage and thus in need of immediate treatment. Today we have very effective direct-acting antivirals (DAAs), which cure more than 90–95 % of all treated patients. However, this treatment is associated with high-costs and the use is limited to the patients with most advanced liver disease in high-income countries. Notably, a majority of the chronic HCV carriers live in resource-poor countries and do not have access to the new effective DAAs. We therefore need to develop alternative treatments for chronic HCV infection such as therapeutic vaccines. The idea with therapeutic vaccines is to reactivate the infected patient’s own immune system. It is well known that patients with chronic HCV infection have dysfunctional immune responses to the virus. Hence, the vaccine should activate HCV-specific T cells that will home to the liver and eradicate the HCV infected hepatocytes. Importantly, one should also consider the combination of a therapeutic vaccine and DAAs as a treatment strategy to equip the resolving patients with post-cure HCV-specific immune responses. This would provide patients with a better protection against reinfection. Numerous genetic vaccine candidates for HCV have been developed and tested in clinical trials with limited effects on viral load and in general inefficient activation of HCV-specific immune responses. In this chapter we describe the rational of developing highly immunogenic vaccines for HCV. Different strategies to improve vaccine immunogenicity and methods to evaluate vaccine efficacy are described. Detailed description of vaccine delivery by intramuscular immunization in combination with in vivo electroporation/electrotransfer (EP/ET) is covered, as well as immunological analysis of primed immune responses by determination of interferon-γ (IFN-γ) production by ELISpot assay and direct ex vivo quantification of HCV NS3/4A-specific CD8+ T cells by pentamer staining. To analyze the in vivo functionality of primed NS3/4A-specific T cells we utilized the in vivo bioluminescence imaging technology. In conclusion, this chapter describes a method to design HCV vaccines and also a protocol to assess their efficacy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST (2013) Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 57:1333–1342

    Article  PubMed  Google Scholar 

  2. Thomas DL (2013) Global control of hepatitis C: where challenge meets opportunity. Nature Med 19:850–858

    Article  CAS  PubMed  Google Scholar 

  3. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR et al (2014) Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. New Engl J Med 370:211–221

    Article  CAS  PubMed  Google Scholar 

  4. Feld JJ, Kowdley KV, Coakley E, Sigal S et al (2014) Treatment of HCV with ABT-450/r–ombitasvir and dasabuvir with ribavirin. New Engl J Med 370:1594–1603

    Article  CAS  PubMed  Google Scholar 

  5. Ahlen G, Frelin L, Brenndorfer ED, Brass A et al (2013) Containing “The Great Houdini” of viruses: combining direct acting antivirals with the host immune response for the treatment of chronic hepatitis C. Drug Resist Updat 16:60–67

    Article  CAS  PubMed  Google Scholar 

  6. Callendret B, Eccleston HB, Hall S, Satterfield W et al (2014) T-cell immunity and hepatitis C virus reinfection after cure of chronic hepatitis C with an interferon-free antiviral regimen in a chimpanzee. Hepatology 60:1531–1540

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Barnes E, Folgori A, Capone S, Swadling L et al (2012) Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med 4:115ra111

    Article  Google Scholar 

  8. Swadling L, Capone S, Antrobus RD, Brown A et al (2014) A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. Sci Transl Med 6:261ra153

    Article  PubMed  PubMed Central  Google Scholar 

  9. Weiland O, Ahlen G, Diepolder H, Jung MC et al (2013) Therapeutic DNA vaccination using in vivo electroporation followed by standard of care therapy in patients with genotype 1 chronic hepatitis C. Mol Therapy 21:1796–1805

    Article  CAS  Google Scholar 

  10. Di Bisceglie AM, Janczweska-Kazek E, Habersetzer F et al (2014) Efficacy of immunotherapy with TG4040, peg-interferon, and ribavirin in a Phase 2 study of patients with chronic HCV infection. Gastroenterology 147:119–131

    Article  PubMed  Google Scholar 

  11. Habersetzer F, Honnet G, Bain C, Maynard-Muet M et al (2011) A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C. Gastroenterology 141:890–899

    Article  CAS  PubMed  Google Scholar 

  12. Klade CS, Schuller E, Boehm T, von Gabain A, Manns MP (2012) Sustained viral load reduction in treatment-naive HCV genotype 1 infected patients after therapeutic peptide vaccination. Vaccine 30:2943–2950

    Article  CAS  PubMed  Google Scholar 

  13. Wedemeyer H, Schuller E, Schlaphoff V, Stauber RE et al (2009) Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C. Vaccine 27:5142–5151

    Article  CAS  PubMed  Google Scholar 

  14. Frelin L, Ahlen G, Alheim M, Weiland O et al (2004) Codon optimization and mRNA amplification effectively enhances the immunogenicity of the hepatitis C virus nonstructural 3/4A gene. Gene Ther 11:522–533

    Article  CAS  PubMed  Google Scholar 

  15. Chen A, Ahlen G, Brenndorfer ED, Brass A et al (2011) Heterologous T cells can help restore function in dysfunctional hepatitis C virus nonstructural 3/4A-specific T cells during therapeutic vaccination. J Immunol 186:5107–5118

    Article  CAS  PubMed  Google Scholar 

  16. Levander S, Sällberg M, Ahlén G, Frelin L. A non-human hepadnaviral adjuvant for hepatitis C virus-based DNA vaccines. Submitted for publication.

    Google Scholar 

  17. Brass A, Frelin L, Milich DR, Sallberg M, Ahlen G (2015) Functional aspects of intrahepatic Hepatitis B Virus-specific T cells induced by therapeutic DNA vaccination. Mol Therapy 23:578–590

    Article  Google Scholar 

  18. Tovey MG, Lallemand C (2010) Adjuvant activity of cytokines. Methods Mol Biol 626:287–309

    Article  CAS  PubMed  Google Scholar 

  19. Applequist SE, Rollman E, Wareing MD, Liden M et al (2005) Activation of innate immunity, inflammation, and potentiation of DNA vaccination through mammalian expression of the TLR5 agonist flagellin. J Immunol 175:3882–3891

    Article  CAS  PubMed  Google Scholar 

  20. Branden LJ, Mohamed AJ, Smith CI (1999) A peptide nucleic acid-nuclear localization signal fusion that mediates nuclear transport of DNA. Nature Biotechnol 17:784–787

    Article  CAS  Google Scholar 

  21. Sallberg M, Frelin L, Ahlen G, Sallberg-Chen M (2015) Electroporation for therapeutic DNA vaccination in patients. Medical Microbiol Immunol 204:131–135

    Article  Google Scholar 

  22. Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH et al (1993) Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259:1745–1749

    Article  CAS  PubMed  Google Scholar 

  23. MacGregor RR, Boyer JD, Ugen KE, Lacy KE et al (1998) First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis 178:92–100

    Article  CAS  PubMed  Google Scholar 

  24. Calarota S, Bratt G, Nordlund S, Hinkula J et al (1998) Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet 351:1320–1325

    Article  CAS  PubMed  Google Scholar 

  25. Aihara H, Miyazaki J (1998) Gene transfer into muscle by electroporation in vivo. Nature Biotechnol 16:867–870

    Article  CAS  Google Scholar 

  26. Ahlen G, Soderholm J, Tjelle T, Kjeken R, Frelin L et al (2007) In vivo electroporation enhances the immunogenicity of hepatitis C virus nonstructural 3/4A DNA by increased local DNA uptake, protein expression, inflammation, and infiltration of CD3+ T cells. J Immunol 179:4741–4753

    Article  CAS  PubMed  Google Scholar 

  27. Gothelf A, Gehl J (2012) What you always needed to know about electroporation based DNA vaccines. Human Vaccines Immunother 8:1694–1702

    Article  CAS  Google Scholar 

  28. Ahlen G, Sallberg M, Frelin L (2013) Methods for monitoring gene gun-induced HBV- and HCV-specific immune responses in mouse models. Methods Mol Biol 940:239–267

    CAS  PubMed  Google Scholar 

  29. Fournillier A, FrelinL JE, Ahlen G et al (2013) A heterologous prime/boost vaccination strategy enhances the immunogenicity of therapeutic vaccines for hepatitis C virus. J Infect Dis 208:1008–1019

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Lin Y, Kwon T, Polo J, Zhu YF et al (2008) Induction of broad CD4+ and CD8+ T-cell responses and cross-neutralizing antibodies against hepatitis C virus by vaccination with Th1-adjuvanted polypeptides followed by defective alphaviral particles expressing envelope glycoproteins gpE1 and gpE2 and nonstructural proteins 3, 4, and 5. J Virol 82:7492–7503

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Pancholi P, Perkus M, Tricoche N, Liu Q, Prince AM (2003) DNA immunization with hepatitis C virus (HCV) polycistronic genes or immunization by HCV DNA priming-recombinant canarypox virus boosting induces immune responses and protection from recombinant HCV-vaccinia virus infection in HLA-A2.1-transgenic mice. J Virol 77:382–390

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The following work was supported by grants from the Swedish Research Council (K2012-99X-22017-01-3), the Swedish Society of Medicine, Goljes Memorial Fund, the Åke Wiberg Foundation, the Ruth and Richard Juhlin Foundation, and from Karolinska Institutet.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Lars Frelin .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer Science+Business Media New York

About this protocol

Cite this protocol

Ahlén, G., Frelin, L. (2016). Methods to Evaluate Novel Hepatitis C Virus Vaccines. In: Thomas, S. (eds) Vaccine Design. Methods in Molecular Biology, vol 1403. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-3387-7_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-3387-7_11

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-3385-3

  • Online ISBN: 978-1-4939-3387-7

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics